Search research articles
Contact Us
Filters
Showing results (61-70 of 103) with videos related to
Page
of 11
Sort By:
Oncology Research and Treatment
|
March 21, 2018
Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder
Gokmen U Erdem, Mutlu Dogan, Abdullah Sakin, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|
April 4, 2019
A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)
Serkan Degirmencioglu, Ozgur Tanriverdi, Serkan Menekse, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 13, 2026
Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG)
Ozden Demir, Bulent Cetin, Ali Alkan, et al.
Cancers
|
June 27, 2024
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study
Yasin Kutlu, Shute Ailia Dae, Feride Yilmaz, et al.
Cancers
|
October 16, 2024
Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study
Ebru Karci, Ahmet Bilici, Buket Bayram, et al.
Scientific Reports
|
July 13, 2025
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study
Maral Martin Mildanoglu, Yasin Kutlu, Onur Bas, et al.
Oncology Research and Treatment
|
August 23, 2019
Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study
Muhammet Ali Kaplan, Sukru Ozaydin, Halis Yerlikaya, et al.
Journal of Gastrointestinal Cancer
|
February 4, 2021
Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group
Mustafa Gürbüz, Erman Akkuş, Abdullah Sakin, et al.
Tumori
|
November 10, 2020
Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer
Mustafa Gürbüz, Erman Akkuş, Abdullah Sakin, et al.
Cancer Investigation
|
December 13, 2021
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 103) with videos related to
Sort By:
Page
of 11
Oncology Research and Treatment
|
March 21, 2018
Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder
Gokmen U Erdem, Mutlu Dogan, Abdullah Sakin, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|
April 4, 2019
A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)
Serkan Degirmencioglu, Ozgur Tanriverdi, Serkan Menekse, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 13, 2026
Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG)
Ozden Demir, Bulent Cetin, Ali Alkan, et al.
Cancers
|
June 27, 2024
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study
Yasin Kutlu, Shute Ailia Dae, Feride Yilmaz, et al.
Cancers
|
October 16, 2024
Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study
Ebru Karci, Ahmet Bilici, Buket Bayram, et al.
Scientific Reports
|
July 13, 2025
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study
Maral Martin Mildanoglu, Yasin Kutlu, Onur Bas, et al.
Oncology Research and Treatment
|
August 23, 2019
Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study
Muhammet Ali Kaplan, Sukru Ozaydin, Halis Yerlikaya, et al.
Journal of Gastrointestinal Cancer
|
February 4, 2021
Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group
Mustafa Gürbüz, Erman Akkuş, Abdullah Sakin, et al.
Tumori
|
November 10, 2020
Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer
Mustafa Gürbüz, Erman Akkuş, Abdullah Sakin, et al.
Cancer Investigation
|
December 13, 2021
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, et al.
Page
of 11